1. Introduction
Oral and implant surgeries are commonly associated with significant postoperative sequelae, including pain, inflammation, and delayed bone healing. These complications can negatively affect patient recovery and the overall success of the surgical intervention. Traditional approaches to pain management, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are effective but have notable limitations, including the risk of dependency, gastrointestinal side effects, and inadequate long-term efficacy [ 1 ]. Consequently, there is an increasing need for safer and more effective alternatives. Cannabinoids, particularly cannabidiol (CBD) and tetrahydrocannabinol (THC), have shown considerable potential in addressing these challenges [ 2 ]. Their therapeutic effects are mediated through the endocannabinoid system (ECS), which plays a key role in regulating pain, inflammation, and immune responses. Specifically, CB1 and CB2 receptors are involved in modulating neuronal transmission and immune activity, respectively ( Figure 1 ) [ 3 , 4 , 5 ].
Cannabis oil, recognized for its antioxidant properties, may help mitigate oxidative damage by scavenging ROS and upregulating antioxidative mechanisms, potentially enhancing wound healing. Additionally, CBD has been shown to influence non-cannabinoid pathways, such as the TRPV1 and serotonin receptors, further contributing to its analgesic and anti-inflammatory properties [ 7 , 8 ]. Beyond these effects, the “entourage effect”, which describes the synergistic interaction between cannabinoids, terpenes, and flavonoids, enhances the therapeutic potential of these compounds. For instance, flavonoids like quercetin and cannflavin amplify the anti-inflammatory and analgesic properties of cannabinoids [ 2 ]. Terpenes such as beta-caryophyllene also play a crucial role, acting as agonists of CB2 receptors to reduce inflammation and pain [ 2 , 8 ]. The selective activation of the CB2 receptor could represent a new therapeutic strategy to reduce osteoclastic activity and bone resorption in patients with Paget bone disease. This approach could also help manage the pain associated with the disease. Treatment with JWH-133, a selective CB2 agonist, resulted in a significant reduction in the number and activation of osteoclasts. On the other hand, the TRPV1 receptor agonist increased osteoclast activity, while its antagonist, I-RTX, led to a decrease in osteoclast activation. In terms of bone resorption activity, CB2 activation with JWH-133 effectively reduced the area of bone resorption, highlighting its potential to control excessive bone degradation. Conversely, the use of the CB2 inhibitor (AM630) resulted in increased bone resorption, further illustrating the regulatory role of CB2 in bone remodeling. However, further studies are needed to validate these results in larger samples [ 9 , 10 ]. CBD acts on bone fracture healing through various mechanisms. First, it stimulates mesenchymal stem cells, which can differentiate into osteoblasts, thereby improving the formation of bone tissue during the fracture healing process. This accelerates bone regeneration, increasing the mechanical strength of the newly formed bone. Additionally, CBD appears to enhance the biomechanical quality of the newly formed bone in association with the increased expression of procollagen-lysine 2-oxoglutarate 5-dioxygenase (PLOD1), making the healed fracture more resistant. However, no significant impact on bone health has been observed in the absence of fractures or damage, suggesting that CBD has a targeted effect mainly when bone repair is needed [ 11 , 12 ].
This encourages the idea that after an implant procedure, a protocolled therapeutic assumption of cannabinoids, terpenes, and flavonoids, might enhance the healing time and increase the osteointegration. While preclinical studies have provided robust evidence for the efficacy of cannabinoids in managing pain and inflammation, as well as promoting bone regeneration, clinical results have been more variable. Furthermore, several literature reviews have explored the use of cannabidiol for oral health, but most have focused primarily on the number of cannabinoid receptors in different dental conditions, without demonstrating the specific effects of these compounds on such conditions [ 13 , 14 , 15 ]. Thus, this systematic review aims to synthesize the current literature on the effect of cannabinoids, focusing on their analgesic and anti-inflammatory properties in bone healing. By examining their mechanisms of action and therapeutic synergies, this study seeks to evaluate their potential for improving outcomes in dentistry.
2. Materials and Methods
A systematic review was conducted using the PRISMA framework [ 16 ]. According to the PICO statement, this systematic review aimed to answer to the question: is the use of cannabinoid drugs (intervention) effective for the management of orofacial pain (primary outcome) in dental patients (population)? Oral lesions and bone healing have been considered as secondary outcomes. Other drugs instead of cannabinoids were used as comparisons. This systematic review was registered on the PROSPERO database (number CRD420250652264). No deviations from the initial protocol were encountered.
2.1. Literature Search
Articles were searched in PubMed, Scopus, and Web of Science up to November 2024 using the MeSH Terms and keywords listed in Table 1 . The software Rayyan (online free program, Cambridge, MA, USA) was used to select articles in duplicate by two blinded authors (MDC, GDP).
A manual search was performed directly from the websites of the following scientific journals: Pharmacology , Pharmacological Research , Clinical Pharmacology and Therapeutics , Dentistry Journal , Biodrugs , and Trends in Pharmacological Sciences . Two authors (MDC, GDP) separately carried out the electronic literature search. After title and abstract screening, the articles were selected for full-text reading. Whenever differences in the judgment of the eligibility of title and abstract occurred, full texts were included for final assessment. All RCT studies, CCTs, cross-sectional studies, case reports, case series, animal studies published until November 2024 about the effects of CBDs on orofacial pain, bone healing after oral surgery and pain linked to soft tissue oral lesions compared to other drugs, have been included. Questionnaires, literature reviews, systematic reviews, and all studies on patients suffering from oncological or psychiatric pathologies were excluded. Articles written in any language other than English were excluded. To identify unpublished or discontinued studies, all authors of the selected studies were contacted and the bibliographies of all selected studies and relevant reviews were checked. Disagreements between the two investigators were solved through discussion; if needed, a third operator (RG) was contacted for final decision.
2.2. Data Extraction
Data were independently extracted by two authors (MDC, GDP) using a pre-determined extraction form. The following data were extracted: publication year, country of origin, type of study design and sample size, type of cannabinoid used (CBD, THC, or others), outcome measures related to pain, inflammation and bone healing, details about the results obtained (including methods of measurement and time intervals), complication rates.
2.3. Risk of Bias Assessment
Two authors (AA and GS) independently assessed the studies in terms of inclusion criteria, relevance, eligibility, and risk of bias following the recommendations of the Joanna Briggs Institute Critical Appraisal tool (JBI) [ 17 ] for randomized-controlled trials, SYRCLE’s risk of bias [ 18 ] for animal studies and QUIN (Quality Assessment Tool for In Vitro Studies) [ 19 ] for in vitro studies in dentistry. Any disagreement was solved by consensus between reviewers and statisticians (PD). The JBI does not provide a range of scores that indicate the overall quality, but considering the relative importance of each domain and its potential impact on the study results and interpreting the domain scores in the context of the study, the studies were classified as having a low risk of bias if most domains score “Yes”, a moderate risk if some domains are rated “No/Unclear”, and a high risk if multiple domains have significant bias or are rated “No”. The SYRCLE’s tool addresses the following types of biases: selection bias, performance bias, attrition bias, detection bias, and reporting bias. A “yes” judgment indicates a low risk of bias; a “no” judgment indicates a high risk of bias; the judgment will be “unclear” if insufficient details have been reported to assess the risk of bias properly. Finally, the QUIN tool consisted of 12 criteria (clearly stated aims/objectives, detailed explanation of sample size calculation, detailed explanation of sampling technique, details of comparison group, detailed explanation of methodology, operator details, randomization, method of measurement of outcome, outcome assessor details, blinding, statistical analysis, and presentation of results) that can be evaluated as adequately specified = 2 points, inadequately specified = 1 point, not specified = 0 point, and not applicable = exclude criteria from calculation. The scores were then added to obtain a total score for a particular in vitro study. The scores thus obtained were used to grade the in vitro study as high-, medium-, or low-risk (>70% = low risk of bias, 50% to 70% = medium risk of bias, and <50% = high risk of bias) by using the following formula: final score = (total score × 100)/(2 × number of criteria applicable).
3. Results
3.1. Selection of Studies
In total, the initial search strategies generated 1097 articles. After duplicate removal, 721 articles remained for title and abstract evaluation. A total of 702 papers were excluded due to mismatch with our search criteria, different evaluated outcomes, and topic. Then, 19 articles were retained for final full text review. Finally, 14 articles [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ] which have so far evaluated the potentially of cannabinoid on orofacial pain, oral inflammation, and bone healing. Reports were excluded if they were narrative reviews, systematic reviews, correspondence, and letters to the editor, as shown in Table 2 [ 34 , 35 , 36 , 37 , 38 , 39 ]. The results of the selected studies were classified under the following subheadings: effect of cannabinoid on orofacial pain, oral inflammation, and bone healing (in vitro or in vivo). Some studies touched upon different characteristics; therefore, they were included in two/three categories called “synergistic effects of cannabinoids”. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram 2020 in Figure 2 depicts the flow of included studies through each phase of the review process.
3.2. Subgroup Analysis
To explore potential variability in outcomes and strengthen the validity of the findings, a subgroup analysis was performed based on the type of condition treated (orofacial pain, oral inflammation, and bone healing), [ Table 3 ] type of cannabinoid used (CBD, THC, and CB2 receptor agonists), [ Table 4 ] study model (preclinical vs. clinical), [ Table 5 ] and mode of administration (topical, oral, or injectable formulations) [ Table 6 ].
3.3. Clinical Results
The main results of the study are reported in Table 7 .
3.3.1. Analgesic Effect/Oral Ulcers Therapy/Oral Gingivostomatitis Therapy
Chrepa, V. and collaborators [ 21 ] investigated the effectiveness and safety of cannabidiol (CBD) as a non-opioid analgesic for emergency dental pain. They showed that CBD significantly reduced pain scores compared to the placebo. CBD at 10 mg/kg (CBD10) and 20 mg/kg (CBD20) doses provided maximum pain relief within 180 min of administration. CBD20 achieved faster onset of significant pain relief (15 min) than CBD10 (30 min). Moreover, both CBD doses significantly increased bite force, indicating improved masticatory function. However, CBD caused minimal adverse effects including sedation (calmness or relaxation), diarrhea, and abdominal pain, which resolved quickly or with minor interventions. In the study of Umpreecha, C. [ 33 ], the authors investigated the safety and efficacy of topical 0.1% cannabidiol (CBD) for managing recurrent aphthous ulcers. No allergic reactions, side effects, or changes in vital signs or blood parameters occurred after CBD use. CBD reduced ulcer size more significantly than placebo at all time points. CBD reduced erythematous size significantly by day 2 and reduced pain compared to placebo by day 5, concluding that topical 0.1% CBD is safe and effective, demonstrating anti-inflammatory effects in early RAU stages and analgesic effects in later stages. Thus, CBD could be an alternative for RAU patients who prefer not to use steroids, except in cases where CBD is contraindicated. As the same way, Qi, X. et al. [ 31 ] showed that CBD oral spray on induced oral ulcers on mice tongue inhibits inflammation, relieves pain, and accelerates lesion closure. Coelho [ 22 ] assessed the clinical efficacy and safety of a commercially available cannabidiol (CBD) oral formulation as an adjunctive pain management treatment for feline chronic gingivostomatitis (FCGS). CBD significantly improved disease severity in cats with FCGS, and the treatment was safe, with no major adverse effects. Ostenfeld [ 31 ] evaluated the postoperative pain-relief efficacy of GW842166 , a noncannabinoid CB2 agonist, in patients undergoing a third molar extraction. Patients received either GW842166 (100 mg or 800 mg), ibuprofen (800 mg initially, followed by 400 mg after 4 h), or placebo preoperatively. GW842166 (at both 100 mg and 800 mg doses) did not provide meaningful postoperative pain relief compared to ibuprofen or placebo in acute dental pain scenarios. Ibuprofen remained superior across all evaluated endpoints. Nitecka-Buchta, A. and collaborators [ 27 ] showed that the application of CBD formulation over masseter muscle reduced the activity of masseter muscles and improved the condition of masticatory muscles in patients with myofascial pain.
3.3.2. Anti-Inflammatory Effect
Five studies [ 20 , 23 , 25 , 28 , 29 ] evaluated the anti-inflammatory effect of CBD, all in induced periodontitis in rats.
Ossola, C. and collaborators [ 28 ] evaluated the effects of the CB2 receptor agonist HU-308 on oral health in rats with induced periodontitis, applied topically to the gingiva daily. The findings showed that HU-308 exhibited anti-inflammatory, bone-protective, and pro-homeostatic effects in rats with induced periodontitis. These findings suggest potential therapeutic benefits of CB2 receptor agonists for managing periodontal disease. As before, the same authors [ 29 ] assessed the effect of long-term treatment with the synthetic cannabinoid methanandamide (Meth-AEA) on the progression of periodontitis in rats. They showed that cannabinoid significantly diminished the alveolar bone loss, compared to rats without treatment. The treatment also reduced the production of some biological mediators of periodontal disease such as tumor necrosis factor alpha and nitric oxide. Also, Se Woong Kim [ 23 ] examined the combined effects of CBD and taurine on inflammatory markers and periodontitis in rats. In rats with periodontitis, treatment with CBD and taurine significantly reduced alveolar bone resorption, periodontal pocket depth, and the distance between the cementoenamel junction (CEJ) and the alveolar bone crest (ABC), suggesting that their combination could be a novel treatment for periodontal disease. According to previous results, Napimoga, M. [ 25 ] tested the effects of CBD in a periodontitis experimental model in rats. Morphometrical analysis of alveolar bone loss demonstrated that CBD-treated animals presented a decreased alveolar bone loss and a lower expression of the activator of nuclear factor-κB ligand RANKL/RANK, along with lower interleukin (IL)-1β and tumor necrosis factor (TNF)-α production. These results indicate that CBD may be useful to control bone resorption during the progression of experimental periodontitis in rats. In the end, Chen, H. [ 20 ], investigated CBD’s anti-inflammatory effects and its potential to protect bone in periodontitis. CBD significantly reduced bone loss in the experimental periodontitis model, downregulated TNF-α, and reduced TLR4 expression in gingival tissues, suggesting that CBD, particularly in topical form, could be an effective therapeutic agent for treating periodontitis.
3.3.3. Bone Healing/Regeneration Effect
Qi, X. and collaborators [ 32 ] investigated the potential of cannabidiol (CBD) to promote odonto/osteogenesis in human dental pulp cells (HDPCs) for applications in vital pulp therapy. CBD demonstrated bi-phasic effects on HDPC viability, enhancing proliferation and cell migration. Moreover, CBD enhanced collagen synthesis (types I and III) and mineral deposition and increased expression of odonto/osteogenic markers, suggesting that CBD has therapeutic potential as a biocompatible agent for enhancing pulp repair and regeneration in dentistry. Nogueira-Filho [ 27 ] investigated the effects of Cannabis sativa (marijuana) smoke on bone healing around titanium implants in rats, exposed to marijuana smoke for 8 min daily. The authors showed deleterious effect on bone healing in the cancellous bone surrounding titanium implants, potentially raising concerns for implant success in marijuana users. According to the previous study, Klein, K. and collaborators [ 24 ] also showed that marijuana, through its active component tetrahydrocannabinol (THC), affects bone remodeling in rats undergoing orthodontic tooth movement.
3.4. Risk of Bias Results
The results of the bias risk assessment for randomized controlled trials (RCTs) included in the review are shown in Table 8 . Only four RCTs were included in the article. Most domains were satisfied; instead, only one domain (“Were outcomes assessors blind to treatment assignment?”) scored “unclear” for one RCT. Despite that, all RCTs resulted as low risk of bias. Nine animal studies were included in the article. The most satisfied domains were selection, performance, and detection bias. Overall, according to SYRCLE’S risk of bias, animal studies included were assessed as having a high risk of bias ( Table 9 ). Finally, only one in vitro study was evaluated as having a low risk of bias according to the nine criteria recognized as applicable ( Table 10 ).
4. Discussion
This systematic review aims to synthesize the current literature on the effect of cannabinoids, focusing on their analgesic, anti-inflammatory, and properties for bone healing. Cannabinoids, the active compounds found in the cannabis plant, have gained increasing attention in medical science due to their potential therapeutic benefits. The clinical importance of cannabinoids lies in their ability to modulate a range of medical conditions, particularly those for which conventional treatments may be limited or ineffective. Cannabinoids interact with the endocannabinoid system (ECS) to modulate pain and inflammation, with CBD showing unique advantages through its interaction with TRPV1 and serotonin receptors [ 40 ]. These mechanisms align with existing evidence and support CBD as a safer alternative to opioids and NSAIDs, as cannabinoids have demonstrated significant potential in controlling postoperative pain and inflammation [ 3 , 41 ].
Cannabinoids have been increasingly used as part of pain management strategies, particularly for chronic pain conditions such as cancer pain, neuropathic pain (e.g., diabetic neuropathy, multiple sclerosis), orofacial pain [ 42 , 43 ], fibromyalgia, arthritis, and chronic lower back pain [ 44 , 45 ]. Tetrahydrocannabinol (THC) modulates pain perception through CB1 receptor activation, reducing pain transmission in the central nervous system [ 46 ]. Cannabidiol (CBD), on the other hand, exerts anti-inflammatory effects by decreasing pro-inflammatory markers such as TNF-α and IL-6 via indirect ECS modulation and interaction with TRPV1 receptors, leading to reduced pain perception [ 47 ]. In clinical studies, patients treated with CBD experienced a 30% reduction in postoperative pain within 24 h compared to those treated with NSAIDs, suggesting that cannabinoids provide an effective non-opioid alternative for pain management [ 48 ]. However, the administration of cannabidiol (CBD) as therapy for orofacial pain or oral ulcers should aim to achieve a clinical effect with minimal side effects. Both acute and chronic CBD treatments were tested on human oral cells, with acute treatment showing more significant effects than chronic treatment, particularly in fibroblasts. Concentrations of CBD ≥50 μM were found to be highly cytotoxic, inducing apoptosis and reducing cell migration. These findings suggest that further investigation is needed to evaluate the dose- and time-dependent effects of CBD to identify the optimal therapeutic dose. In the study of Umpreecha C. [ 33 ], the authors showed that topical 0.1% cannabidiol (CBD) had no allergic reactions or side effects.
Other clinical indications include neurological disorders (e.g., epilepsy, multiple sclerosis, especially for spasticity and muscle spasms, Parkinson’s disease, for motor symptoms and tremors, Alzheimer’s disease), anxiety and mood disorders, and inflammatory and autoimmune diseases (e.g., rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis) [ 49 , 50 , 51 ].
Subgroup analysis revealed both consistencies and notable variabilities across the included studies. The analgesic and anti-inflammatory effects of cannabidiol (CBD) were consistently observed across clinical, preclinical, and in vitro models, particularly in managing orofacial pain and periodontitis. However, variability emerged in the context of bone healing, where outcomes depended on the cannabinoid type, delivery route, and study model. For instance, while preclinical studies reported enhanced bone regeneration and reduced resorption following CBD or CB2 receptor agonist administration, clinical evidence remains limited and less conclusive. Moreover, oral and topical routes of cannabinoid delivery demonstrated different degrees of efficacy, with topical applications showing faster localized pain relief and fewer side effects. These findings underscore the importance of stratified analysis to identify which cannabinoid formulations and administration methods are most effective for specific oral conditions, ultimately strengthening the validity and clinical applicability of the overall findings.
Moreover, additional specificity regarding the different types of cannabinoids studied could help contextualize the therapeutic implications more precisely. Among the studies included in this review, cannabidiol (CBD) was the most frequently investigated compound, noted for its non-psychoactive profile and broad anti-inflammatory, analgesic, and regenerative effects. Only one study explored tetrahydrocannabinol (THC) [ 24 ]. Synthetic analogs, such as HU-308 (a selective CB2 receptor agonist) and methanandamide (Meth-AEA, a CB1 agonist), were also evaluated in preclinical models, with findings suggesting significant anti-inflammatory and osteoprotective effects. This distinction between phytocannabinoids (CBD, THC) and synthetic analogs (e.g., HU-308, Meth-AEA) is important, as they differ in receptor selectivity, side effect profiles, and potential clinical applications. Greater granularity in future research comparing these agents head-to-head would be valuable in determining their optimal use in dental and oral surgical contexts.
Further studies could focus on CBD’s anti-inflammatory and regenerative properties, as it promotes bone regeneration and accelerates osseointegration by activating CB2 receptors, a topic particularly relevant for dental implantology [ 52 , 53 ]. This activation stimulates osteoblast activity while inhibiting osteoclast-mediated bone resorption. Preclinical studies have shown that CBD accelerates callus formation, enhances bone density, and improves the biomechanical strength of regenerated tissue. Additionally, CBD’s interaction with PLOD1, an enzyme crucial for collagen stabilization, contributes to the mechanical resilience of bone tissue [ 54 ]. These findings underscore the significant potential of cannabinoids as adjuvant therapies to improve outcomes in dental implantology and support their broader role in regenerative medicine and surgical applications. In addition, the synergistic effects between cannabinoids, terpenes, and flavonoids, known as the entourage effect, significantly enhance the therapeutic potential of individual compounds [ 55 ]. For instance, beta-caryophyllene, a terpene, acts as a CB2 receptor agonist, complementing CBD’s anti-inflammatory properties, while flavonoids like quercetin enhance antioxidant and anti-inflammatory effects, further reducing pain and inflammation. Preclinical models have shown that combining CBD with terpenes, such as myrcene, enhances cellular permeability, improving pain and inflammation control [ 56 ]. Additionally, CBD’s anxiolytic effects, mediated through its interaction with serotonin 5-HT1A receptors, help manage preoperative anxiety, which can positively influence surgical outcomes [ 57 ]. Clinical studies indicate that CBD treatment can reduce anxiety by up to 40% compared to a placebo, improving patient comfort and facilitating smoother postoperative recovery [ 58 ]. These findings highlight CBD’s potential as a holistic therapeutic option in dentistry, While the current findings highlight the promising therapeutic potential of cannabinoids—particularly CBD—in managing orofacial pain, oral inflammation, and promoting bone healing, their immediate integration into dental practice remains premature. Although several preclinical studies have demonstrated consistent analgesic and anti-inflammatory effects, and a few human trials report favorable outcomes with minimal side effects, the overall clinical evidence is still limited by small sample sizes, variability in dosing, cannabinoid formulations, and outcome measures. Furthermore, most randomized controlled trials evaluated short-term effects, and therefore long-term safety, optimal dosing protocols, and drug interactions remain unclear. Therefore, while these results offer a compelling rationale for further research, especially in dental pain and postoperative management, more large-scale, standardized clinical trials are required before cannabinoids can be fully endorsed as routine adjuncts in dental care.
Furthermore, as with every drug, also CBDs caused adverse effects included sedation (calmness or relaxation), diarrhea, and abdominal pain [ 59 ]. Nevertheless, they were resolved quickly or with minor interventions. Moreover, chronic treatments with concentrations of CBD ≥ 50 μM were found to be highly cytotoxic, inducing apoptosis and reducing cell migration [ 60 ].
This stated the need to evaluate the dose- and time-dependent effects of CBD to identify the optimal therapeutic dose.
This systematic review has several limitations that must be acknowledged. First, the included studies were highly heterogeneous in terms of study design, cannabinoid type (CBD, THC, CB1/CB2 agonists, cannabis smoke), administration route (topical, oral, systemic), and outcome measures. Second, more than half of the studies included were preclinical (animal or in vitro), and nine of the animal studies were judged to have a high risk of bias, weakening the strength of the evidence base. Third, although four randomized controlled trials were included, one was rated as moderate risk of bias and they evaluated different conditions (e.g., acute dental pain, myofascial pain, and oral ulcers), reducing the generalizability of findings. Finally, due to the variability in outcome reporting and the lack of standardized effect size data, meta-analysis could not be performed, limiting quantitative synthesis.
5. Conclusions
Within the limitations of this review, cannabinoids—especially cannabidiol (CBD)—demonstrated potential in managing orofacial pain, reducing inflammation, and promoting bone healing. However, these conclusions are drawn from a heterogeneous body of evidence, including multiple preclinical studies with high risk of bias and clinical trials with varying outcomes and endpoints. Notably, studies using different cannabinoid agents (e.g., THC, CB2 agonists, and cannabis smoke) were grouped without sufficient comparative analysis, limiting the strength of overarching conclusions. Therefore, while the therapeutic application of cannabinoids in dentistry is promising, especially as non-opioid alternatives, current evidence does not yet support immediate integration into clinical practice. Rigorous, well-powered, and standardized clinical trials are needed to confirm efficacy, determine safety, and guide dosage and formulation strategies.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Author Contributions
Conceptualization, G.d.P. and P.B.; methodology, M.D.C.; software, A.A.; validation, G.S. and P.B.; formal analysis, M.D.C.; investigation, P.B.; data curation, R.G.; writing—original draft preparation, R.G.; writing—review and editing, P.B.; supervision, G.S.; project administration, A.A. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data are included in the manuscript.
Conflicts of Interest
The authors declare no conflicts of interest.
References
1. Ghlichloo I. Gerriets V. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) StatPearls [Internet] StatPearls Publishing Treasure Island, FL, USA 2024 31613522
2. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin Br. J. Pharmacol. 2008 153 199 215 10.1038/sj.bjp.0707442 17828291 PMC2219532
3. Castillo-Arellano J. Canseco-Alba A. Cutler S.J. León F. The Polypharmacological Effects of Cannabidiol Molecules 2023 28 3271 10.3390/molecules28073271 37050032 PMC10096752
4. Fiore M. Alfieri A. Di Franco S. Petrou S. Damiani G. Pace M.C. Medicinal cannabis products for the treatment of acute pain World J. Clin. Cases 2023 11 2670 2676 37214578 10.12998/wjcc.v11.i12.2670 PMC10198104
5. Votrubec C. Tran P. Lei A. Brunet Z. Bean L. Olsen B.W. Sharcma D. Cannabinoid therapeutics in orofacial pain management: A systematic review Aust. Dent. J. 2022 67 314 327 10.1111/adj.12934 36082517 PMC10087667
6. Datta S. Ramamurthy P.C. Anand U. Singh S. Singh A. Dhanjal D.S. Wonder or evil?: Multifaceted health hazards and health benefits of Cannabis sativa and its phytochemicals Saudi J. Biol. Sci. 2021 28 7290 7313 10.1016/j.sjbs.2021.08.036 34867033 PMC8626265
7. Israni D.K. Raghani N.R. Soni J. Shah M. Prajapati B.G. Chorawala M.R. Mangmool S. Singh S. Chittasupho C. Harnessing Cannabis sativa Oil for Enhanced Skin Wound Healing: The Role of Reactive Oxygen Species Regulation Pharmaceutics 2024 16 1277 10.3390/pharmaceutics16101277 39458608 PMC11510192
8. Kasai S. Nishizawa D. Hasegawa J. Fukuda K.I. Ichinohe T. Nagashima M. Hayashida M. Ikeda K. Short Tandem Repeat Variation in the CNR1 Gene Associated With Analgesic Requirements of Opioids in Postoperative Pain Management Front. Genet. 2022 13 815089 35360861 10.3389/fgene.2022.815089 PMC8963810
9. Stephens K.L. Heineman J.T. Forster G.L. Timko M.P. DeGeorge B.R. Cannabinoids and pain for the plastic surgeon: What is the evidence? Ann. Plast. Surg. 2022 88 (Suppl. 5) S508 S511 10.1097/SAP.0000000000003128 35502947
10. Rossi F. Tortora C. Punzo F. Bellini G. Argenziano M. Di Paola A. Torella M. Perrotta S. The Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma Int. J. Mol. Sci. 2019 20 1919 10.3390/ijms20081919 31003519 PMC6514542
11. Raphael-Mizrahi B. Gabet Y. The Cannabinoids Effect on Bone Formation and Bone Healing Curr. Osteoporos. Rep. 2020 18 433 438 10.1007/s11914-020-00607-1 32705630
12. Idris A.I. Ralston S.H. Role of cannabinoids in the regulation of bone remodeling Front. Endocrinol. 2012 3 136 10.3389/fendo.2012.00136 23181053 PMC3499879
13. Abidi A.H. Alghamdi S.S. Derefinko K. A critical review of cannabis in medicine and dentistry: A look back and the path forward Clin. Exp. Dent. Res. 2022 8 613 631 10.1002/cre2.564 35362240 PMC9209799
14. Lowe H. Toyang N. Steele B. Bryant J. Ngwa W. Nedamat K. The Current and Potential Application of Medicinal Cannabis Products in Dentistry Dent. J. 2021 9 106 10.3390/dj9090106 34562980 PMC8466648
15. Bellocchio L. Patano A. Inchingolo A.D. Inchingolo F. Dipalma G. Isacco C.G. de Ruvo E. Rapone B. Mancini A. Lorusso F. Cannabidiol for Oral Health: A New Promising Therapeutical Tool in Dentistry Int. J. Mol. Sci. 2023 24 9693 10.3390/ijms24119693 37298644 PMC10253521
16. Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. Shamseer L. Tetzlaff J.M. Akl E.A. Brennan S.E. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews BMJ 2021 372 n71 10.1136/bmj.n71 33782057 PMC8005924
17. Moola S. Munn Z. Tufanaru C. Aromataris E. Sears K. Sfetcu R. Currie M. Lisy K. Qureshi R. Mattis P. Chapter 7: Systematic reviews of etiology and risk JBI Man. Evid. Synth. 2020 5 217 269
18. Hooijmans C.R. Rovers M.M. de Vries R.B. Leenaars M. Ritskes-Hoitinga M. Langendam M.W. SYRCLE’s risk of bias tool for animal studies BMC Med. Res. Methodol. 2014 14 43 10.1186/1471-2288-14-43 24667063 PMC4230647
19. Sheth V.H. Shah N.P. Jain R. Bhanushali N. Bhatnagar V. Development and validation of a risk-of-bias tool for assessing in vitro studies conducted in dentistry: The QUIN J. Prosthet. Dent. 2024 131 1038 1042 10.1016/j.prosdent.2022.05.019 35752496
20. Chen H. Liu Y. Yu S. Li C. Gao B. Zhou X. Cannabidiol attenuates periodontal inflammation through inhibiting TLR4/NF-κB pathway J. Periodontal Res. 2023 58 697 707 10.1111/jre.13118 37143211
21. Chrepa V. Villasenor S. Mauney A. Kotsakis G. Macpherson L. Cannabidiol as an Alternative Analgesic for Acute Dental Pain J. Dent. Res. 2024 103 235 242 10.1177/00220345231200814 37910667 PMC10900863
22. Coelho J.C. Duarte N. Bento da Silva A. Bronze M.D.R. Mestrinho L.A. Placebo-Controlled Trial of Daily Oral Cannabidiol as Adjunctive Treatment for Cats with Chronic Gingivostomatitis Animals 2023 13 2716 10.3390/ani13172716 37684980 PMC10487179
23. Kim S.W. Shrestha S.K. Chuluunbaatar B.A. Soh Y. Combination of Cannabidiol with Taurine Synergistically Treated Periodontitis in Rats Biomol. Ther. 2025 33 203 209 10.4062/biomolther.2024.104 39632669 PMC11704405
24. Klein K.P. Guastaldi F.P.S. Pereira H.S.G. He Y. Lukas S.E. Dronabinol inhibits alveolar bone remodeling in tooth movement of rats Am. J. Orthod. Dentofac. Orthop. 2022 161 e215 e222 10.1016/j.ajodo.2021.07.012 34924285
25. Napimoga M.H. Benatti B.B. Lima F.O. Alves P.M. Campos A.C. Pena-Dos-Santos D.R. Severino F.P. Cunha F.Q. Guimarães F.S. Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats Int. Immunopharmacol. 2009 9 216 222 10.1016/j.intimp.2008.11.010 19070683
26. Nitecka-Buchta A. Nowak-Wachol A. Wachol K. Walczyńska-Dragon K. Olczyk P. Batoryna O. Kempa W. Baron S. Myorelaxant effect of transdermal cannabidiol in patients with temporomandibular disorders: A randomized, double-blind trial J. Clin. Med. 2020 8 1886 10.3390/jcm8111886 PMC6912397 31698733
27. Nogueira-Filho G.R. Cadide T. Rosa B.T. Neiva T.G. Tunes R. Peruzzo D. Nociti F.H. Jr. César-Neto J.B. Cannabis sativa smoke inhalation decreases bone filling around titanium implants: A histomorphometric study in rats Implant Dent. 2008 17 461 470 10.1097/ID.0b013e31818c5a2a 19077584
28. Ossola C.A. Surkin P.N. Mohn C.E. Elverdin J.C. Fernández-Solari J. Anti-Inflammatory and Osteoprotective Effects of Cannabinoid-2 Receptor Agonist HU-308 in a Rat Model of Lipopolysaccharide-Induced Periodontitis J. Periodontol. 2016 87 725 734 10.1902/jop.2016.150612 26846967
29. Ossola C.A. Surkin P.N. Pugnaloni A. Mohn C.E. Elverdin J.C. Fernandez-Solari J. Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats Inflamm. Res. 2012 61 941 948 10.1007/s00011-012-0485-z 22581275
30. Ostenfeld T. Price J. Albanese M. Bullman J. Guillard F. Meyer I. Leeson R. Costantin C. Ziviani L. Nocini P.F. A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction Clin. J. Pain. 2011 27 668 676 10.1097/AJP.0b013e318219799a 21540741
31. Qi X. Lin W. Wu Y. Li Q. Zhou X. Li H. Xiao Q. Wang Y. Shao B. Yuan Q. CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome J. Dent. Res. 2022 101 206 215 10.1177/00220345211024528 34269108
32. Qi X. Liu C. Li G. Luan H. Li S. Yang D. Zhou Z. Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell J. Dent. 2021 109 103673 10.1016/j.jdent.2021.103673 33872753
33. Umpreecha C. Bhalang K. Charnvanich D. Luckanagul J. Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: A randomized controlled trial BMC Complement. Med. Ther. 2023 23 57 10.1186/s12906-023-03886-0 36803360 PMC9940329
34. Borsani E. Majorana A. Cocchi M.A. Conti G. Bonadeo S. Padovani A. Lauria G. Bardellini E. Rezzani R. Rodella L.F. Epithelial expression of vanilloid and cannabinoid receptors: A potential role in burning mouth syndrome pathogenesis Histol. Histopathol. 2014 29 523 533 24190005 10.14670/HH-29.10.523
35. de Andrade Silva S. Velozo C. de Almeida Souto Montenegro L. de Sousa W.V. da Cunha Isaltino M. de Fátima Formiga Melo Diniz M. de Albuquerque D.S. Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial J. Endod. 2024 50 1698 1704 10.1016/j.joen.2024.10.010 39505200
36. Nogueira-Filho G.R. Todescan S. Shah A. Rosa B.T. Tunes Uda R. Cesar Neto J.B. Impact of cannabis sativa (marijuana) smoke on alveolar bone loss: A histometric study in rats J. Periodontol. 2011 82 1602 1607 10.1902/jop.2011.100362 21513470
37. Ossola C.A. Rodas J.A. Balcarcel N.B. Astrauskas J.I. Elverdin J.C. Fernández-Solari J. Signs of alveolar bone damage in early stages of periodontitis and its prevention by stimulation of cannabinoid receptor 2. Model in rats Acta Odontol. Latinoam. 2020 33 143 152 10.54589/aol.33/2/143 32920617
38. Qi X. Liu C. Li G. Al-Alfe D. Paurazas S. Askar M. Yang D. Zhou Z. Evaluation of Cannabinoids on the Odonto/Osteogenesis in Human Dental Pulp Cells In Vitro J. Endod. 2021 47 444 450 10.1016/j.joen.2020.12.005 33352148
39. Qian H. Jin Z. Li S. Huo N. Han C. Sang H. Activation of CB2 cannabinoid receptors: A novel therapeutic strategy to accelerate osseointegration of dental implants Med. Hypotheses 2009 72 311 313 10.1016/j.mehy.2008.09.047 19027245
40. Carrascosa A.J. Navarrete F. Saldaña R. García-Gutiérrez M.S. Montalbán B. Navarro D. Gómez-Guijarro F.M. Gasparyan A. Murcia-Sánchez E. Torregrosa A.B. Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality Int. J. Mol. Sci. 2024 25 6268 10.3390/ijms25116268 38892456 PMC11172912
41. Bruni N. Della Pepa C. Oliaro-Bosso S. Pessione E. Gastaldi D. Dosio F. Cannabinoid Delivery Systems for Pain and Inflammation Treatment Molecules 2018 23 2478 10.3390/molecules23102478 30262735 PMC6222489
42. Pereira S.R. Tello Velasquez J. Duggan S. Ivanisevic B. McKenna J.P. McCreary C. Downer E.J. Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: Focus on the actions of cannabinoids Eur. J. Neurosci. 2022 55 1032 1050 10.1111/ejn.14712 32091630
43. Canfora F. Calabria E. Cuocolo R. Ugga L. Buono G. Marenzi G. Gasparro R. Pecoraro G. Aria M. D’Aniello L. Burning Fog: Cognitive Impairment in Burning Mouth Syndrome Front. Aging Neurosci. 2021 13 727417 10.3389/fnagi.2021.727417 34475821 PMC8406777
44. Mücke M. Phillips T. Radbruch L. Petzke F. Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults Cochrane Database Syst. Rev. 2018 3 CD012182 29513392 10.1002/14651858.CD012182.pub2 PMC6494210
45. Vučković S. Srebro D. Vujović K.S. Vučetić Č. Prostran M. Cannabinoids and Pain: New Insights from Old Molecules Front. Pharmacol. 2018 9 1259 10.3389/fphar.2018.01259 30542280 PMC6277878
46. Manzanares J. Julian M. Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes Curr. Neuropharmacol. 2006 4 239 257 10.2174/157015906778019527 18615144 PMC2430692
47. Martinez Naya N. Kelly J. Corna G. Golino M. Abbate A. Toldo S. Molecular and Cellular Mechanisms of Action of Cannabidiol Molecules 2023 28 5980 10.3390/molecules28165980 37630232 PMC10458707
48. Safi K. Sobieraj J. Błaszkiewicz M. Żyła J. Salata B. Dzierżanowski T. Tetrahydrocannabinol and Cannabidiol for Pain Treatment-An Update on the Evidence Biomedicines 2024 12 307 10.3390/biomedicines12020307 38397910 PMC10886939
49. Singh K. Bhushan B. Chanchal D.K. Sharma S.K. Rani K. Yadav M.K. Porwal P. Kumar S. Sharma A. Virmani T. Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review Behav. Neurol. 2023 2023 8825358 10.1155/2023/8825358 37868743 PMC10586905
50. Sarris J. Sinclair J. Karamacoska D. Davidson M. Firth J. Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review BMC Psychiatry 2020 20 24 10.1186/s12888-019-2409-8 31948424 PMC6966847
51. Filippini G. Minozzi S. Borrelli F. Cinquini M. Dwan K. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis Cochrane Database Syst. Rev. 2022 5 CD013444 10.1002/14651858.CD013444.pub2 35510826 PMC9069991
52. Paoletta M. Moretti A. Liguori S. Di Paola A. Tortora C. Argenziano M. Rossi F. Iolascon G. Role of the Endocannabinoid/Endovanilloid System in the Modulation of Osteoclast Activity in Paget’s Disease of Bone Int. J. Mol. Sci. 2021 22 10158 10.3390/ijms221810158 34576321 PMC8469971
53. Apostu D. Lucaciu O. Mester A. Benea H. Oltean-Dan D. Onisor F. Baciut M. Bran S. Cannabinoids and bone regeneration Drug Metab Rev. 2019 51 65 75 10.1080/03602532.2019.1574303 30702341
54. Kogan N.M. Melamed E. Wasserman E. Raphael B. Breuer A. Stok K.S. Sondergaard R. Escudero A.V. Baraghithy S. Attar-Namdar M. Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts J. Bone Miner. Res. 2015 30 1905 1913 10.1002/jbmr.2513 25801536
55. Ferber S.G. Namdar D. Hen-Shoval D. Eger G. Koltai H. Shoval G. Shbiro L. Weller A. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders Curr. Neuropharmacol. 2020 18 87 96 10.2174/1570159X17666190903103923 31481004 PMC7324885
56. Liktor-Busa E. Keresztes A. LaVigne J. Streicher J.M. Largent-Milnes T.M. Analgesic Potential of Terpenes Derived from Cannabis sativa Pharmacol. Rev. 2021 73 98 126 10.1124/pharmrev.120.000046 34663685 PMC11060501
57. Resstel L.B. Tavares R.F. Lisboa S.F. Joca S.R. Corrêa F.M. Guimarães F.S. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioral and cardiovascular responses to acute restraint stress in rats Br. J. Pharmacol. 2009 156 181 188 10.1111/j.1476-5381.2008.00046.x 19133999 PMC2697769
58. Melas P.A. Scherma M. Fratta W. Cifani C. Fadda P. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research Int. J. Mol. Sci. 2021 22 1863 10.3390/ijms22041863 33668469 PMC7917759
59. Huestis M.A. Solimini R. Pichini S. Pacifici R. Carlier J. Busardò F.P. Cannabidiol Adverse Effects and Toxicity Curr. Neuropharmacol. 2019 17 974 989 10.2174/1570159X17666190603171901 31161980 PMC7052834
60. Pagano S. Valenti C. Negri P. Billi M. Di Michele A. Bruscoli S. Febo M. Coniglio M. Marinucci L. Acute and chronic cannabidiol treatment: In vitro toxicological aspects on human oral cells Food Chem. Toxicol. 2024 185 114513 10.1016/j.fct.2024.114513 38342230